<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: cases already", fill: "#353839"},
{source: "1: cases already", target: "1: materially affect us", fill: "#353839"},
{source: "1: materially affect us", target: "1: financial condition", fill: "#353839"},
{source: "1: financial condition", target: "1: operations", fill: "#353839"},
{source: "1: cases already", target: "6: As of December ", fill: "#cfb53b"},
{source: "6: As of December ", target: "6: approximately", fill: "#cfb53b"},
{source: "6: approximately", target: "6: indebtedness", fill: "#cfb53b"},
{source: "6: indebtedness", target: "6: additional borrowing capacity under", fill: "#cfb53b"},
{source: "6: additional borrowing capacity under", target: "6: revolving portions", fill: "#cfb53b"},
{source: "6: revolving portions", target: "6: facilities", fill: "#cfb53b"},
{source: "6: As of December ", target: "10: difficult", fill: "#d2691e"},
{source: "10: difficult", target: "10: obligations under", fill: "#d2691e"},
{source: "10: obligations under", target: "10: senior subordinated", fill: "#d2691e"},
{source: "10: senior subordinated", target: "10: facilities", fill: "#d2691e"},
{source: "10: facilities", target: "10: cash flow from", fill: "#d2691e"},
{source: "10: cash flow from", target: "10: operations", fill: "#d2691e"},
{source: "10: operations", target: "10: pay principal", fill: "#d2691e"},
{source: "10: pay principal", target: "10: interest on", fill: "#d2691e"},
{source: "10: interest on", target: "10: indebtedness", fill: "#d2691e"},
{source: "10: indebtedness", target: "10: cash available", fill: "#d2691e"},
{source: "10: cash available", target: "10: activities", fill: "#d2691e"},
{source: "10: activities", target: "10: debt service obligations", fill: "#d2691e"},
{source: "10: debt service obligations", target: "10: capital expenditures", fill: "#d2691e"},
{source: "10: capital expenditures", target: "10: introduction", fill: "#d2691e"},
{source: "10: introduction", target: "10: new products andor", fill: "#d2691e"},
{source: "10: new products andor", target: "10: opportunities", fill: "#d2691e"},
{source: "10: opportunities", target: "10: acquisitions research", fill: "#d2691e"},
{source: "10: acquisitions research", target: "10: development", fill: "#d2691e"},
{source: "10: development", target: "10: product design enhancements", fill: "#d2691e"},
{source: "10: product design enhancements", target: "10: flexibility", fill: "#d2691e"},
{source: "10: flexibility", target: "10: market conditions leaving us", fill: "#d2691e"},
{source: "10: market conditions leaving us", target: "10: general economic conditions", fill: "#d2691e"},
{source: "10: general economic conditions", target: "10: industries", fill: "#d2691e"},
{source: "10: industries", target: "10: additional financing", fill: "#d2691e"},
{source: "10: additional financing", target: "10: competitive disadvantage compared", fill: "#d2691e"},
{source: "10: competitive disadvantage compared", target: "10: competitors", fill: "#d2691e"},
{source: "10: competitors", target: "10: fluctuations", fill: "#d2691e"},
{source: "10: fluctuations", target: "10: interest rate environment with", fill: "#d2691e"},
{source: "10: interest rate environment with", target: "10: bears interest at variable", fill: "#d2691e"},
{source: "10: difficult", target: "11: interest on", fill: "#013220"},
{source: "11: interest on", target: "11: facility", fill: "#013220"},
{source: "11: facility", target: "11: operations", fill: "#013220"},
{source: "11: operations", target: "11: additional loans under", fill: "#013220"},
{source: "11: additional loans under", target: "11: covenant compliance", fill: "#013220"},
{source: "11: covenant compliance", target: "11: potentially from", fill: "#013220"},
{source: "11: potentially from", target: "11: equity offerings", fill: "#013220"},
{source: "11: interest on", target: "21: acquisitions", fill: "#800020"},
{source: "21: acquisitions", target: "21: businesses", fill: "#800020"},
{source: "21: businesses", target: "21: acquisitions will", fill: "#800020"},
{source: "21: acquisitions will", target: "21: lenders apos", fill: "#800020"},
{source: "21: lenders apos", target: "21: facility", fill: "#800020"},
{source: "21: acquisitions", target: "22: lenders apos", fill: "#bf4f51"},
{source: "22: lenders apos", target: "22: consent under", fill: "#bf4f51"},
{source: "22: consent under", target: "22: facility", fill: "#bf4f51"},
{source: "22: facility", target: "22: acquisitions", fill: "#bf4f51"},
{source: "22: acquisitions", target: "22: Wampole Division of MedPointe Inc ", fill: "#bf4f51"},
{source: "22: Wampole Division of MedPointe Inc ", target: "22: rapid diagnostics", fill: "#bf4f51"},
{source: "22: rapid diagnostics", target: "22: diagnostics", fill: "#bf4f51"},
{source: "22: diagnostics", target: "22: Abbott Laboratories ", fill: "#bf4f51"},
{source: "22: Abbott Laboratories ", target: "22: or the Abbott ", fill: "#bf4f51"},
{source: "22: or the Abbott ", target: "22: Ischemia Inc ", fill: "#bf4f51"},
{source: "22: Ischemia Inc ", target: "22: or the Determine ", fill: "#bf4f51"},
{source: "22: or the Determine ", target: "22: Terapeutica SAU ", fill: "#bf4f51"},
{source: "22: Terapeutica SAU ", target: "22: technologies", fill: "#bf4f51"},
{source: "22: lenders apos", target: "START_HERE", fill: "#bf4f51"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_mergers_and_acquisitions_by_Alphabet">List of mergers and acquisitions by Alphabet</a></td>
      <td>Google is a computer software and a web search engine company that acquired, on average, more than one company per week in 2010 and 2011. The table below is an incomplete list of acquisitions, with each acquisition listed being for the respective company in its entirety, unless otherwise specified.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Library_acquisitions">Library acquisitions</a></td>
      <td>Library acquisitions is the department of a library responsible for the selection and purchase of materials or resources. The department may select vendors, negotiate consortium pricing, arrange for standing orders, and select individual titles or resources.Libraries, both physical and digital, usually have four common broad goals that help dictate these responsibilities.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_management">Facility management</a></td>
      <td>Facility management, or facilities management, (FM) is a professional management discipline focused on the efficient and effective delivery of logistics and other support services related to real property, it encompasses multiple disciplines to ensure functionality, comfort, safety and efficiency of the built environment by integrating people, place, process and technology, as defined by the International Organization for Standardization (ISO). The profession is certified through Global Facility Management Association (Global FM) member organizations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_ID">Facility ID</a></td>
      <td>The facility ID number, also called a FIN or facility identifier, is a unique integer number of one to six digits, assigned by the U.S. Federal Communications Commission (FCC) Media Bureau to each broadcast station in the FCC Consolidated Database System (CDBS) and Licensing and Management System (LMS) databases, among others.\nBecause CDBS includes information about foreign stations which are notified to the U.S. under the terms of international frequency coordination agreements, FINs are also assigned to affected foreign stations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_facility">Health facility</a></td>
      <td>A health facility is, in general, any location where healthcare is provided. Health facilities range from small clinics and doctor's offices to urgent care centers and large hospitals with elaborate emergency rooms and trauma centers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_location">Facility location</a></td>
      <td>The study of facility location problems (FLP), also known as location analysis, is a branch of operations research and computational geometry concerned with the optimal placement of facilities to minimize transportation costs while considering factors like avoiding placing hazardous materials near housing, and competitors' facilities. The techniques also apply to cluster analysis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mint_(facility)">Mint (facility)</a></td>
      <td>A mint is an industrial facility which manufactures coins that can be used as currency.\nThe history of mints correlates closely with the history of coins.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Telecommunications_facility">Telecommunications facility</a></td>
      <td>In telecommunications, a facility is defined by Federal Standard 1037C as:\n\nA fixed, mobile, or transportable structure, including (a) all installed electrical and electronic wiring, cabling, and equipment and (b) all supporting structures, such as utility, ground network, and electrical supporting structures.\nA network-provided service to users or the network operating administration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pine_Gap">Pine Gap</a></td>
      <td>Pine Gap is the commonly used name for a satellite surveillance base and Australian Earth station approximately 18 kilometres (11 mi) south-west of the town of Alice Springs, Northern Territory in the centre of Australia. It is jointly operated by Australia and the United States, and since 1988 it has been officially called the Joint Defence Facility Pine Gap (JDFPG); previously, it was known as Joint Defence Space Research Facility.The station is partly run by the US Central Intelligence Agency (CIA), US National Security Agency (NSA), and US National Reconnaissance Office (NRO) and is a key contributor to the NSA's global interception effort, which included the ECHELON program.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_mergers_and_acquisitions_by_Meta_Platforms">List of mergers and acquisitions by Meta Platforms</a></td>
      <td>Meta Platforms (formerly Facebook, Inc.) is a technology company that has acquired 91 other companies, including WhatsApp. The WhatsApp acquisition closed at a steep $16 billion; more than $40 per user of the platform.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Knowledge_acquisition">Knowledge acquisition</a></td>
      <td>Knowledge acquisition is the process used to define the rules and ontologies required for a knowledge-based system. The phrase was first used in conjunction with expert systems to describe the initial tasks associated with developing an expert system, namely finding and interviewing domain experts and capturing their knowledge via rules, objects, and frame-based ontologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_acquisitions_by_Oracle">List of acquisitions by Oracle</a></td>
      <td>This is a listing of Oracle Corporation's corporate acquisitions, including acquisitions of both companies and individual products.\nOracle's version does not include value of the acquisition.See also Category:Sun Microsystems acquisitions (Sun was acquired by Oracle).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bolt-on_acquisition">Bolt-on acquisition</a></td>
      <td>Bolt-on acquisition refers to the acquisition of smaller companies, usually in the same line of business, that presents strategic value. This is in contrast to primary acquisitions of other companies which are generally in different industries, require larger investments, or are of similar size to the acquiring company.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ben_Ashkenazy">Ben Ashkenazy</a></td>
      <td>Ben Ashkenazy (born 1968/69) is an American billionaire real estate developer. He is the founder, CEO, and majority owner of Ashkenazy Acquisition Corporation, which has a $12 billion property portfolio.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_&amp;_Acquisitions">Mergers &amp; Acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>INVERNESS MEDICAL INNOVATIONS INC      ITEM 1A    RISK FACTORS                  The  risk  factors  described below may <font color="blue">materially</font> impact your     <font color="blue">investment</font> in our company or may in the future, and, in some <font color="blue">cases already</font>     do, <font color="blue"><font color="blue">materially</font> affect us</font> and our business, <font color="blue">financial condition</font> and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider these <font color="blue">factors with respect</font> to     your  <font color="blue">investment</font> in our securities</td>
    </tr>
    <tr>
      <td>This section includes or refers to     certain forward-looking statements; you should read the <font color="blue">explanation</font> of the     <font color="blue">qualifications</font> and <font color="blue">limitation</font>s on such forward-looking statements beginning     on pages 2 and 30 of this report</td>
    </tr>
    <tr>
      <td>Our business has substantial <font color="blue">indebtedness</font>, which could, among other things,     make it more <font color="blue">difficult</font> for us to satisfy our <font color="blue">debt <font color="blue">obligations</font></font>, require us to     use a large portion of our <font color="blue"><font color="blue">cash flow</font> from</font> <font color="blue">operations</font> to repay and service     our debt or otherwise create <font color="blue">liquidity problems</font>, limit our <font color="blue">flexibility</font> to     adjust to <font color="blue">market <font color="blue">conditions</font></font>, place us at a <font color="blue">competitive disadvantage</font> and     expose us to <font color="blue">interest rate <font color="blue">fluctuations</font></font></td>
    </tr>
    <tr>
      <td>We  currently  have,  and  we  <font color="blue">will likely continue</font> to have, a     substantial  amount  of  <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had     <font color="blue">approximately</font>   dlra262dtta5 million  in  aggregate  principal  <font color="blue">indebtedness</font>     outstanding,  of  which  dlra93dtta2 million  is  secured  <font color="blue">indebtedness</font>, and     dlra11dtta0 million of <font color="blue"><font color="blue">additional</font> borrowing capacity under</font> the <font color="blue">revolving portions</font>     of our credit <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>In addition, subject to <font color="blue">restrictions</font> in our credit     <font color="blue">facilities</font> and the <font color="blue">indenture governing</font> our dlra150dtta0 million in outstanding     8^3/4prca <font color="blue">senior subordinated</font> notes, or the <font color="blue">senior subordinated</font> notes, we may     incur <font color="blue">additional</font> <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>During the fiscal years ended <font color="blue">December </font>31,     2005 and 2004, we recorded dlra21dtta8 million and dlra22dtta1 million, <font color="blue">respectively</font>, of     <font color="blue">interest expense</font> related to our <font color="blue">indebtedness</font>, which included dlra2dtta3 million     and dlra4dtta2 million, <font color="blue">respectively</font>, in non-cash interest primarily related to     <font color="blue">amortization</font> of <font color="blue">debt origination costs</font></td>
    </tr>
    <tr>
      <td>Our substantial <font color="blue">indebtedness</font> could affect our future <font color="blue">operations</font> in     <font color="blue">important ways</font></td>
    </tr>
    <tr>
      <td>For example, it could:          •                 make it more <font color="blue">difficult</font> to satisfy our <font color="blue"><font color="blue">obligations</font> under</font> the                 <font color="blue">senior subordinated</font> notes, our credit <font color="blue">facilities</font> and our other                 debt-related instruments;          •                 require  us  to  use a large portion of our <font color="blue"><font color="blue">cash flow</font> from</font>                 <font color="blue">operations</font> to <font color="blue">pay principal</font> and <font color="blue">interest on</font> our <font color="blue">indebtedness</font>,                 which would reduce the amount of <font color="blue">cash available</font> to finance our                 <font color="blue">operations</font> and other business <font color="blue">activities</font> and may require us, in                 order to meet our <font color="blue">debt service <font color="blue">obligations</font></font>, to delay or reduce                 <font color="blue">capital <font color="blue">expenditure</font>s</font> or the <font color="blue">introduction</font> of <font color="blue">new products</font> and/or                 forego business <font color="blue">opportunities</font>, including <font color="blue"><font color="blue">acquisition</font>s</font>, research                 and <font color="blue">development</font> projects or <font color="blue">product design <font color="blue">enhancements</font></font>;          •                 limit our <font color="blue">flexibility</font> to adjust to <font color="blue">market <font color="blue">conditions</font></font>, leaving us                 vulnerable in a downturn in <font color="blue">general economic <font color="blue">conditions</font></font> or in                 our business and less able to plan for, or react to, changes in                 our business and the <font color="blue">industries</font> in which we operate;          •                 impair our ability to obtain <font color="blue"><font color="blue">additional</font> financing</font>;          •                 place  us  at  a  <font color="blue">competitive disadvantage</font> compared to our                 <font color="blue">competitors</font> that have less debt; and          •                 expose us to <font color="blue">fluctuations</font> in the <font color="blue">interest rate environment with</font>                 respect to our <font color="blue">indebtedness</font> that <font color="blue">bears interest at variable</font>                 rates</td>
    </tr>
    <tr>
      <td>We expect to obtain the money to pay our expenses and to pay the     principal and <font color="blue">interest on</font> the <font color="blue">senior subordinated</font> notes, our senior credit     <font color="blue">facility</font> and our other debt from <font color="blue"><font color="blue">cash flow</font> from</font> our <font color="blue">operations</font> and from     <font color="blue"><font color="blue">additional</font> loans under</font> our senior credit <font color="blue">facility</font>, subject to continued     <font color="blue">covenant compliance</font>, and <font color="blue"><font color="blue">potentially</font> from</font> other debt or <font color="blue">equity offerings</font></td>
    </tr>
    <tr>
      <td>Our ability to meet our <font color="blue">expenses thus depends on</font> our <font color="blue">future performance</font>,     <font color="blue">which will</font> be <font color="blue">affected by financial</font>, business, economic and other factors</td>
    </tr>
    <tr>
      <td>We will not be able to control many of these factors, such as economic     <font color="blue">conditions</font> in the markets in which we operate and pressure from <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that our <font color="blue"><font color="blue">cash flow</font> will</font> be sufficient to allow us to     <font color="blue">pay principal</font> and <font color="blue">interest on</font> our debt and meet our other <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________       If our <font color="blue">cash flow</font> and <font color="blue">capital resources prove</font> inadequate, we could face     substantial <font color="blue">liquidity problems</font> and might be required to dispose of material     assets or <font color="blue">operations</font>, restructure or refinance our debt, including the     notes,  <font color="blue">seek <font color="blue">additional</font> equity capital</font> or borrow more money</td>
    </tr>
    <tr>
      <td>In     addition, the terms of existing or <font color="blue">future debt <font color="blue">agreement</font>s</font>, including the     credit <font color="blue"><font color="blue">agreement</font> governing</font> our senior credit <font color="blue">facility</font> and the indenture     governing the <font color="blue">senior subordinated</font> notes, <font color="blue">may restrict us from adopting</font> any     of these <font color="blue"><font color="blue">alternative</font>s</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into <font color="blue"><font color="blue">agreement</font>s governing</font></font> our <font color="blue">indebtedness</font> that subject us     to  various <font color="blue">restrictions</font> that may limit our ability to pursue business     <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">agreement</font>s governing</font> our <font color="blue">indebtedness</font>, including the credit     <font color="blue"><font color="blue">agreement</font> governing</font> our senior credit <font color="blue">facility</font> and the <font color="blue">indenture governing</font>     the <font color="blue">senior subordinated</font> notes, subject us to various <font color="blue">restrictions</font> on our     ability to engage in certain <font color="blue">activities</font>, including, among other things, our     ability to:          •                 incur <font color="blue">additional</font> <font color="blue">indebtedness</font>;          •                 <font color="blue">pay dividends</font> or make <font color="blue"><font color="blue">distribution</font>s</font> or repurchase or redeem our                 stock;          •                 acquire other <font color="blue">businesses</font>;          •                 make <font color="blue">investment</font>s;          •                 make loans to or extend credit for the benefit of <font color="blue">third parties</font>                 or our <font color="blue">subsidiaries</font>;          •                 <font color="blue"><font color="blue">enter into</font> <font color="blue">transaction</font>s with affiliates</font>;          •                 <font color="blue">raise <font color="blue">additional</font> capital</font>;          •                 make capital or <font color="blue">finance lease <font color="blue">expenditure</font>s</font>;          •                 dispose of or <font color="blue">encumber assets</font>; and          •                 consolidate, merge or sell all or <font color="blue">substantially</font> all of our                 assets</td>
    </tr>
    <tr>
      <td>These  <font color="blue">restrictions</font>  may  limit our ability to pursue business     <font color="blue">opportunities</font> or strategies that we <font color="blue">would otherwise</font> consider to be in our     <font color="blue">best interests</font></td>
    </tr>
    <tr>
      <td>In particular, all <font color="blue"><font color="blue">acquisition</font>s</font> of other <font color="blue">businesses</font>, other     than very small <font color="blue"><font color="blue">acquisition</font>s</font>, will require us to obtain our lenders &amp;apos  consent     under our senior credit <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We have been required to obtain, and have     obtained, our lenders &amp;apos  <font color="blue">consent under</font> our senior credit <font color="blue">facility</font> in order to     complete our <font color="blue"><font color="blue">acquisition</font>s</font> of the Wampole Division of MedPointe Inc, or     Wampole, Ostex International, Inc, or Ostex, Applied Biotech, Inc, or ABI,     the <font color="blue">rapid <font color="blue"><font color="blue">diagnostic</font>s</font></font> business that we acquired from <font color="blue">Abbott Laboratories </font>in     2003, or the 2003 Abbott <font color="blue">rapid <font color="blue"><font color="blue">diagnostic</font>s</font></font> business, Ischemia, Inc, or     Ischemia, Binax, Inc, or Binax, the Determine/DainaScreen business that we     acquired from <font color="blue">Abbott Laboratories </font>in 2005, <font color="blue">or the <font color="blue">Determine </font></font>business, Thermo     BioStar Inc, or BioStar, Innogenetics Diagnostica y Terapeutica SAU, or     IDT, and CLONDIAG chip <font color="blue">technologies</font> GmbH, or Clondiag</td>
    </tr>
    <tr>
      <td>In addition, we are     required to obtain our lenders &amp;apos  consent in order to consummate our recently     announced <font color="blue">agreement</font> to acquire <font color="blue">certain assets from</font> ACON Laboratories, or the     ACON <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>Our senior credit <font color="blue">facilities</font> contain certain financial covenants that we may     not <font color="blue">satisfy which</font>, if not satisfied, could result in the <font color="blue">acceleration</font> of the     <font color="blue">amounts due under</font> our credit <font color="blue">facilities</font> and the <font color="blue">limitation</font> of our ability to     <font color="blue">borrow <font color="blue">additional</font> funds</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had <font color="blue">approximately</font> dlra89dtta0 million of     <font color="blue">indebtedness</font> outstanding under our senior credit <font color="blue">facility</font> and <font color="blue">approximately</font>     dlra11dtta0 million of <font color="blue"><font color="blue">additional</font> borrowing capacity thereunder</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">agreement</font>s     governing this <font color="blue">facility</font> subject us to <font color="blue">various financial</font> and other covenants     with which we <font color="blue">must comply on</font> an ongoing or <font color="blue">periodic basis</font></td>
    </tr>
    <tr>
      <td>These include     <font color="blue">covenants pertaining</font> to fixed charge coverage, <font color="blue">capital <font color="blue">expenditure</font>s</font>, various     leverage ratios, minimum EBITDA and minimum cash                                         12       _________________________________________________________________       <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If we violate any of these covenants, there may be a material     adverse effect on us</td>
    </tr>
    <tr>
      <td>Most notably, our <font color="blue">outstanding debt under</font> our senior     credit <font color="blue">facility</font> could become immediately due and payable, our <font color="blue">lenders could</font>     <font color="blue">proceed against</font> any collateral securing such <font color="blue">indebtedness</font>, and our ability     to <font color="blue">borrow <font color="blue">additional</font> funds</font> in the <font color="blue">future may</font> be limited</td>
    </tr>
    <tr>
      <td>A <font color="blue">default under</font> any of our <font color="blue"><font color="blue">agreement</font>s governing</font> our <font color="blue">indebtedness</font> could     result in a default and <font color="blue">acceleration</font> of <font color="blue">indebtedness</font> under other <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">agreement</font>s governing</font> our <font color="blue">indebtedness</font>, including our senior     credit <font color="blue">facility</font> and the <font color="blue">indenture governing</font> the <font color="blue">senior subordinated</font> notes,     contain cross-default provisions whereby a <font color="blue">default under</font> one <font color="blue">agreement</font> could     result in a default and <font color="blue">acceleration</font> of our repayment <font color="blue"><font color="blue">obligations</font> under</font>     other <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>Even if new     financing were available, it may not be <font color="blue">on <font color="blue">commercially</font> reasonable terms</font> or     terms that are acceptable to us</td>
    </tr>
    <tr>
      <td>If some or all of our <font color="blue">indebtedness</font> is in     default for any reason, our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>We may not be able to satisfy our <font color="blue">debt <font color="blue">obligations</font></font> upon a change of control,     which  could  limit  our <font color="blue">opportunity</font> to <font color="blue">enter into</font> a change of control     <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>Upon the occurrence of a  &amp;quote change of control, &amp;quote  as defined in the     <font color="blue">indenture governing</font> the <font color="blue">senior subordinated</font> notes, <font color="blue">each holder</font> of our senior     subordinated notes will have the right to require us to purchase the notes     at a price equal to 101prca of the principal amount, together with any accrued     and <font color="blue">unpaid interest</font></td>
    </tr>
    <tr>
      <td>Our failure to purchase, or give notice of purchase of,     the <font color="blue">senior subordinated</font> notes would be a <font color="blue">default under</font> the indenture, which     would in turn be a <font color="blue">default under</font> our senior credit <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>In addition, a     change of <font color="blue">control may constitute</font> an event of <font color="blue">default under</font> our senior credit     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">default under</font> our senior credit <font color="blue">facility</font> would result in an     event  of <font color="blue">default under</font> our 10prca subordinated notes and, if the lenders     <font color="blue">accelerate</font>  the  debt  under our senior credit <font color="blue">facility</font>, the indenture     governing the <font color="blue">senior subordinated</font> notes, and may result in the <font color="blue">acceleration</font>     of any of our other <font color="blue">indebtedness</font> outstanding at the time</td>
    </tr>
    <tr>
      <td>As a result, if we     do not have enough cash to repay all of our <font color="blue">indebtedness</font> or to repurchase     all of the <font color="blue">senior subordinated</font> notes, we may be limited in the change of     control <font color="blue">transaction</font>s that we may pursue</td>
    </tr>
    <tr>
      <td>Our  <font color="blue"><font color="blue">acquisition</font>s</font>  may not be profitable, and the <font color="blue">integration</font> of these     <font color="blue">businesses</font> may be costly and <font color="blue">difficult</font> and may cause <font color="blue">disruption</font> to our     business</td>
    </tr>
    <tr>
      <td>We have, since commencing <font color="blue">activities</font> in November 2001, acquired and     we have attempted to integrate, or we are in the process of <font color="blue">integrating</font>,     into our <font color="blue">operations</font> Unipath Limited and its associated companies and assets,     or  the  Unipath business, IVC Industries, Inc</td>
    </tr>
    <tr>
      <td>(now doing business as     Inverness Medical Nutritionals Group, or IMN), Wampole, Ostex, ABI, the 2003     Abbott <font color="blue">rapid <font color="blue"><font color="blue">diagnostic</font>s</font></font> business, Ischemia, Binax, the <font color="blue">Determine </font>business,     BioStar,  IDT  and  Clondiag</td>
    </tr>
    <tr>
      <td>We  have  also made a number of smaller     <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">ultimate success</font> of all of our <font color="blue"><font color="blue">acquisition</font>s</font> depends, in     part, on our ability to realize the anticipated synergies, cost savings and     growth <font color="blue">opportunities</font> from <font color="blue">integrating</font> these <font color="blue">businesses</font> or <font color="blue">assets into</font> our     existing <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>However, the successful <font color="blue">integration</font> of <font color="blue">independent</font>     <font color="blue">businesses</font> or assets is a complex, costly and time-consuming process</td>
    </tr>
    <tr>
      <td>The     <font color="blue">difficult</font>ies of <font color="blue">integrating</font> companies and acquired assets include among     others:          •                 <font color="blue">consolidating</font>  <font color="blue">manufacturing</font>  and research and <font color="blue">development</font>                 <font color="blue">operations</font>, where <font color="blue">appropriate</font>;          •                 <font color="blue">integrating</font> newly acquired <font color="blue">businesses</font> or <font color="blue"><font color="blue">product line</font>s</font> into a                 <font color="blue">uniform financial</font> reporting system;          •                 coordinating sales, <font color="blue">distribution</font> and <font color="blue">marketing functions</font>;                                         13       _________________________________________________________________       •            <font color="blue">establishing</font> or expanding <font color="blue">manufacturing</font>, sales, <font color="blue">distribution</font> and            <font color="blue">marketing functions</font> in order to <font color="blue">accommodate newly</font> acquired <font color="blue">businesses</font>            or <font color="blue"><font color="blue">product line</font>s</font>;     •            preserving  the  important licensing, research and <font color="blue">development</font>,            <font color="blue">manufacturing</font> and supply, <font color="blue">distribution</font>, marketing, customer and other            <font color="blue">relationships</font>;     •            minimizing the diversion of <font color="blue">management</font>apstas <font color="blue">attention from</font> ongoing            business concerns; and     •            <font color="blue">coordinating geographically separate organizations</font></td>
    </tr>
    <tr>
      <td>We may not accomplish the <font color="blue">integration</font> of our <font color="blue"><font color="blue">acquisition</font>s</font> smoothly     or <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>The diversion of the attention of our <font color="blue"><font color="blue">management</font> from</font> our     current  <font color="blue">operations</font>  to  the  <font color="blue">integration</font>  effort and any <font color="blue">difficult</font>ies     <font color="blue">encountered</font> in combining <font color="blue">operations</font> could <font color="blue">prevent us from</font> realizing the full     benefits anticipated to result from these <font color="blue"><font color="blue">acquisition</font>s</font> and <font color="blue"><font color="blue">adversely</font> affect</font>     our  other  <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Additionally,  the  costs <font color="blue">associated with</font> the     <font color="blue">integration</font> of our <font color="blue"><font color="blue">acquisition</font>s</font> can be substantial</td>
    </tr>
    <tr>
      <td>To the extent that we     incur  <font color="blue">integration</font>  costs that are not anticipated when we finance our     <font color="blue"><font color="blue">acquisition</font>s</font>, these unexpected costs could <font color="blue">adversely</font> impact our liquidity or     force us to <font color="blue">borrow <font color="blue">additional</font> funds</font></td>
    </tr>
    <tr>
      <td>Ultimately, the value of any business     or asset that we have acquired may not be <font color="blue">greater than</font> or equal to its     <font color="blue">purchase price</font></td>
    </tr>
    <tr>
      <td>If we choose to acquire or invest in new and complementary <font color="blue">businesses</font>,     products  or  <font color="blue">technologies</font>  instead of developing <font color="blue">them ourselves</font>, such     <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue">investment</font>s could disrupt our business and, <font color="blue"><font color="blue">depending on</font> how</font>     we finance these <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue">investment</font>s, could result in the use of     <font color="blue"><font color="blue"><font color="blue">significant</font> amount</font>s</font> of cash</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on our ability to <font color="blue">continually enhance</font>     and broaden our <font color="blue">product offerings</font> in response to changing <font color="blue">technologies</font>,     <font color="blue">customer demands</font> and <font color="blue">competitive pressures</font></td>
    </tr>
    <tr>
      <td>Accordingly, from time to time     we may seek to acquire or invest in <font color="blue">businesses</font>, products or <font color="blue">technologies</font>     instead of developing <font color="blue">them ourselves</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>and <font color="blue">investment</font>s involve     <font color="blue">numerous risks</font>, including:          •                 the <font color="blue">inability</font> to complete the <font color="blue">acquisition</font> or <font color="blue">investment</font>;          •                 <font color="blue">disruption</font> of our ongoing <font color="blue">businesses</font> and diversion of <font color="blue">management</font>                 attention;          •                 <font color="blue">difficult</font>ies in <font color="blue">integrating</font> the acquired entities, products or                 <font color="blue">technologies</font>;          •                 <font color="blue">difficult</font>ies in operating the acquired business profitably;          •                 <font color="blue">difficult</font>ies in <font color="blue">transitioning</font> key customer, <font color="blue">distributor</font> and                 supplier <font color="blue">relationships</font>;          •                 risks <font color="blue">associated with</font> entering markets in which we have no or                 limited prior experience; and          •                 <font color="blue">unanticipated costs</font></td>
    </tr>
    <tr>
      <td>In addition, any future <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue">investment</font>s may result in:          •                 issuances of dilutive equity securities, which may be sold at a                 discount to <font color="blue">market price</font>;          •                 use of <font color="blue"><font color="blue"><font color="blue">significant</font> amount</font>s</font> of cash;          •                 the incurrence of debt;          •                 the <font color="blue">assumption</font> of <font color="blue"><font color="blue">significant</font> liabilities</font>;          •                 <font color="blue">unfavorable financing terms</font>;          •                 large one-time expenses; and          •                 the creation of <font color="blue">certain <font color="blue">intangible assets</font></font>, including goodwill,                 the write-down of which may result in <font color="blue"><font color="blue">significant</font> charges</font> to                 earnings</td>
    </tr>
    <tr>
      <td>Any of these factors could <font color="blue">materially</font> harm our business or our     operating results</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________       If  goodwill  and/or  other <font color="blue">intangible assets</font> that we have recorded in     <font color="blue"><font color="blue">connection</font> with</font> our <font color="blue"><font color="blue">acquisition</font>s</font> of other <font color="blue">businesses</font> become impaired, we     could have to take <font color="blue"><font color="blue">significant</font> charges</font> against earnings</td>
    </tr>
    <tr>
      <td>In  <font color="blue"><font color="blue">connection</font> with</font> the <font color="blue">accounting</font> for our <font color="blue"><font color="blue">acquisition</font>s</font> of the     Unipath business, Wampole, Ostex, ABI, the 2003 Abbott <font color="blue">rapid <font color="blue"><font color="blue">diagnostic</font>s</font></font>     <font color="blue"><font color="blue">product line</font>s</font>, Ischemia, Binax, the <font color="blue">Determine </font>business, BioStar, IDT and     Clondiag, we have recorded, or expect to record, a <font color="blue"><font color="blue">significant</font> amount</font> of     goodwill and other <font color="blue">intangible assets</font></td>
    </tr>
    <tr>
      <td>Under current <font color="blue">accounting</font> guidelines,     we must assess, at least annually and <font color="blue">potentially</font> more frequently, whether     the value of goodwill and other <font color="blue">intangible assets</font> has <font color="blue">been impaired</font></td>
    </tr>
    <tr>
      <td>Any     reduction or <font color="blue">impairment</font> of the value of goodwill or other <font color="blue">intangible assets</font>     will result in a charge against earnings which could <font color="blue">materially</font> <font color="blue">adversely</font>     affect our reported results of <font color="blue">operations</font> in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>We could experience <font color="blue">significant</font> <font color="blue">manufacturing</font> delays, <font color="blue">disruption</font>s to our     <font color="blue">ongoing research</font> and <font color="blue">development</font> and <font color="blue"><font color="blue">increased production</font> costs</font> if <font color="blue">Unilever     </font>is  unable  to <font color="blue">successfully</font> assign or sublease to us the lease for the     multi-purpose <font color="blue">facility</font> that we <font color="blue">currently use</font> in Bedford, England</td>
    </tr>
    <tr>
      <td>One of our primary operating <font color="blue">facilities</font> is located in Bedford,     England</td>
    </tr>
    <tr>
      <td><font color="blue">The Bedford </font><font color="blue">facility</font> is a multi-purpose <font color="blue">facility</font> that is registered     with  the  FDA, contains state-of-the-art research laboratories and is     equipped with specialized <font color="blue">manufacturing</font> equipment</td>
    </tr>
    <tr>
      <td>This <font color="blue">facility</font> currently     provides the <font color="blue">manufacturing</font> for most of our Clearblue and Clearview products,     serves as our <font color="blue">primary research</font> and <font color="blue">development</font> center and serves as the     <font color="blue">administrative center</font> for our European <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We also use this <font color="blue">facility</font>     to <font color="blue">manufacture</font> the digital and non-digital e</td>
    </tr>
    <tr>
      <td><font color="blue">t pregnancy tests</font> for Pfizer     in <font color="blue"><font color="blue">connection</font> with</font> our supply <font color="blue">arrangements</font> with Pfizer for these products</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently using</font> the Bedford <font color="blue">facility</font> pursuant to our <font color="blue">acquisition</font>     <font color="blue">agreement</font> with Unilever relating to our <font color="blue">acquisition</font> of the Unipath business     in late 2001</td>
    </tr>
    <tr>
      <td>Unilever <font color="blue">currently leases</font> this <font color="blue">facility</font> from a <font color="blue">third party</font>     landlord</td>
    </tr>
    <tr>
      <td>Pursuant to the terms of Unileverapstas lease, Unilever <font color="blue">cannot assign</font>     the lease or sublet the Bedford <font color="blue">facility</font> to <font color="blue">us without first</font> obtaining the     landlordapstas consent</td>
    </tr>
    <tr>
      <td>The landlord has not <font color="blue">yet consented</font> to, and may not in     the <font color="blue">future consent</font> to, an <font color="blue">assignment</font> of the lease or a sublease to us</td>
    </tr>
    <tr>
      <td>The     terms of our <font color="blue">acquisition</font> <font color="blue">agreement</font> obligate Unilever to provide to us the     benefit of its lease <font color="blue">of the Bedford </font><font color="blue">facility</font></td>
    </tr>
    <tr>
      <td><font color="blue">If Unilever </font>is unable to     <font color="blue">successfully</font> acquire <font color="blue">such consent</font> or <font color="blue">otherwise enable us</font> to realize the     benefit of Unileverapstas lease <font color="blue">of the Bedford </font><font color="blue">facility</font>, or if its lease is     terminated, we may be forced to <font color="blue">renegotiate</font> a lease <font color="blue">of the Bedford </font><font color="blue">facility</font>     on <font color="blue">substantially</font> less favorable terms or <font color="blue">seek <font color="blue">alternative</font></font> means of producing     our  products,  conducting  our  research  and  housing  our  <font color="blue">European     </font><font color="blue">administrative staff</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">either case</font>, we may experience <font color="blue">increased production</font>     costs  or  <font color="blue">manufacturing</font>  delays,  <font color="blue">which could <font color="blue">prevent us from</font> meeting</font>     <font color="blue">contractual</font>   supply  <font color="blue">obligations</font>  or  <font color="blue">jeopardize</font>  important  customer     <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>We may also suffer <font color="blue">disruption</font>s to our <font color="blue">ongoing research</font> and     <font color="blue">development</font> while we are resolving these issues</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that     we will be able to <font color="blue">renegotiate</font> a lease for the Bedford <font color="blue">facility</font> on terms     that  are  acceptable to us or find an acceptable <font color="blue">replacement</font> for this     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Any one or more of these <font color="blue">events may</font> have a material adverse effect     on us</td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">manufacturing</font> problems or delays, which could result in     <font color="blue">decreased revenues</font> or <font color="blue">increased costs</font></td>
    </tr>
    <tr>
      <td>Many  of  our  <font color="blue">manufacturing</font> processes are complex and require     specialized and expensive equipment</td>
    </tr>
    <tr>
      <td><font color="blue">Replacement </font>parts for our specialized     equipment can be expensive and, in some cases, can require <font color="blue">lead times</font> of up     to a year to acquire</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">private label</font> <font color="blue">consumer <font color="blue">diagnostic</font></font>     products business, and our <font color="blue">private label</font> and <font color="blue">bulk <font color="blue">nutritional <font color="blue">supplements</font></font></font>     business in particular, rely on operational efficiency to mass produce     <font color="blue">products at low margins per</font> unit</td>
    </tr>
    <tr>
      <td>We also rely on numerous <font color="blue">third parties</font> to     <font color="blue">supply production materials</font> and in some <font color="blue">cases there may</font> not be <font color="blue">alternative</font>     <font color="blue">sources immediately available</font></td>
    </tr>
    <tr>
      <td>In addition, we currently rely on <font color="blue">approximately</font> ten <font color="blue">significant</font>     third-party  <font color="blue">manufacture</font>rs, as well as numerous other <font color="blue">less <font color="blue">significant</font></font>     <font color="blue">manufacture</font>rs, to produce many of our <font color="blue"><font color="blue">professional</font> <font color="blue">diagnostic</font> products</font>                                         15       _________________________________________________________________       and <font color="blue">certain components</font> of our <font color="blue"><font color="blue">consumer <font color="blue">diagnostic</font></font> products</font></td>
    </tr>
    <tr>
      <td>In addition, we     <font color="blue">manufacture</font>  the  products acquired with the <font color="blue">Determine </font>business from a     <font color="blue">facility</font> in Matsudo, Japan that is made available to us, and <font color="blue">with support</font>     services  provided  by,  Abbott  Laboratories</td>
    </tr>
    <tr>
      <td>Any <font color="blue">event impacting</font> our     <font color="blue">manufacturing</font> <font color="blue">facilities</font>, our <font color="blue">manufacturing</font> systems or equipment, or our     contract <font color="blue">manufacture</font>rs or suppliers, including, without <font color="blue">limitation</font>, wars,     terrorist <font color="blue">activities</font>, natural disasters and outbreaks of <font color="blue">infectious disease</font>,     <font color="blue">could delay</font> or <font color="blue">suspend shipments</font> of products or the release of <font color="blue">new products</font>     or could result in the delivery of inferior products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">revenues from</font> the     <font color="blue">affected products would decline</font> or we <font color="blue">could incur losses until such</font> time as     we were able to restore our <font color="blue">production processes</font> or put in place <font color="blue">alternative</font>     contract  <font color="blue">manufacture</font>rs  or  suppliers</td>
    </tr>
    <tr>
      <td>Even though we carry business     <font color="blue">interruption</font>  insurance  policies, we <font color="blue">may suffer losses as</font> a result of     business  <font color="blue">interruption</font>s  that  exceed the <font color="blue">coverage available under</font> our     <font color="blue">insurance policies</font></td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">difficult</font>ies that may delay or prevent our <font color="blue">development</font>,     <font color="blue">introduction</font> or marketing of new or <font color="blue">enhanced products</font></td>
    </tr>
    <tr>
      <td>We  intend  to  continue  to  invest in product and <font color="blue">technology</font>     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of new or <font color="blue">enhanced products</font> is a complex and     uncertain   process</td>
    </tr>
    <tr>
      <td>We  may  experience  research  and  <font color="blue">development</font>,     <font color="blue">manufacturing</font>, marketing and other <font color="blue">difficult</font>ies that <font color="blue">could delay</font> or prevent     our <font color="blue">development</font>, <font color="blue">introduction</font> or marketing of <font color="blue">new products</font> or <font color="blue">enhancements</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that:          •                 any of the products under <font color="blue">development</font> will prove to be <font color="blue">effective</font>                 in <font color="blue">clinical trials</font>;          •                 we  will  be able to obtain, in a <font color="blue">timely manner</font> or at all,                 <font color="blue">regulatory approval</font> to market any of our products that are in                 <font color="blue">development</font> or contemplated;          •                 any of <font color="blue">such products</font> can be <font color="blue">manufacture</font>d at acceptable cost and                 with <font color="blue">appropriate</font> quality; or          •                 any <font color="blue">such products</font>, if and when approved, can be <font color="blue">successfully</font>                 marketed</td>
    </tr>
    <tr>
      <td>The <font color="blue">factors listed</font> above, as well as <font color="blue">manufacturing</font> or <font color="blue">distribution</font>     problems, or other <font color="blue">factors beyond</font> our control, <font color="blue">could delay</font> new product     launches</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">cannot assure</font> you that the <font color="blue">market will accept</font>     these products</td>
    </tr>
    <tr>
      <td>Accordingly, there is no assurance that our <font color="blue">overall revenues</font>     <font color="blue">will increase</font> if and when <font color="blue">new products</font> are launched</td>
    </tr>
    <tr>
      <td>Our failure to meet strict regulatory <font color="blue">requirements</font> could require us to pay     fines, incur other costs or even close our <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">facilities</font> and <font color="blue">manufacturing</font> techniques <font color="blue">generally</font> must conform     to standards that are <font color="blue">established by government agencies</font>, including those of     European and other foreign <font color="blue">governments</font>, as well as the FDA, and, to a lesser     extent, the US Drug Enforcement Administration, or the DEA, and local     health agencies</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulatory agencies may conduct periodic audits</font> of     our <font color="blue">facilities</font> or our processes to monitor our <font color="blue">compliance with applicable</font>     <font color="blue">regulatory standards</font></td>
    </tr>
    <tr>
      <td>If a <font color="blue">regulatory agency</font> finds that we fail to comply     with the <font color="blue">appropriate</font> <font color="blue">regulatory standards</font>, it may impose fines on us, delay     or withdraw pre-market <font color="blue">clearances</font> or other <font color="blue">regulatory approval</font>s or if such a     <font color="blue">regulatory agency</font> determines that our non-compliance is severe, it may close     our <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">adverse action by</font> an applicable <font color="blue">regulatory agency</font> could     impair our ability to produce our products in a cost-<font color="blue">effective</font> and timely     manner in order to meet our customers &amp;apos  demands</td>
    </tr>
    <tr>
      <td>We may also be required to     bear other costs or take other actions that may have a <font color="blue">negative <font color="blue">impact on</font></font>     our <font color="blue">future sales</font> and profits</td>
    </tr>
    <tr>
      <td>In March 2005, our ABI subsidiary was <font color="blue">informed by</font> the FDA that based     <font color="blue">on inspectional findings</font> that included <font color="blue">data integrity</font> and <font color="blue">design control</font>     issues, ABI had become subject to the FDAapstas Application Integrity Policy</td>
    </tr>
    <tr>
      <td>As     a result, the FDA is obligated to defer the review of any pending or future     <font color="blue">applications</font> made by ABI until the FDA determines that ABI has resolved     these  issues</td>
    </tr>
    <tr>
      <td>ABI  currently has no <font color="blue">applications</font> pending</td>
    </tr>
    <tr>
      <td>ABI is not     <font color="blue">restricted from introducing new tests outside</font> of the <font color="blue">United States</font>, or from     selling  products  <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font><font color="blue">based on</font> any existing 510(k)s</td>
    </tr>
    <tr>
      <td>However,                                         16       _________________________________________________________________       ABI withdrew certain 510(k)s related to its drugs of <font color="blue">abuse products</font> that     were cited by the FDA, and a Class III recall (<font color="blue">based on</font> our <font color="blue">assessment</font> that     any  hazard  to  the <font color="blue">public health</font> is unlikely) was undertaken for the     <font color="blue">corresponding products</font></td>
    </tr>
    <tr>
      <td>ABI is in the <font color="blue">final stages</font> of both an internal and     <font color="blue">external audit</font>, and is committed to taking any actions required by those     audits  in  order  to  fulfill  its  regulatory <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>It is our     understanding at this time that the FDA <font color="blue">action applies only</font> to ABI and does     not  otherwise  restrict  our  ability,  or  the  ability of our other     <font color="blue">subsidiaries</font>, to submit <font color="blue">applications</font> <font color="blue">to the FDA </font>or <font color="blue">commercialize</font> products</td>
    </tr>
    <tr>
      <td>However, the scope <font color="blue">of the FDA </font>action is uncertain, and may have a negative     <font color="blue">impact on</font> our <font color="blue">future sales</font> and profits</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">agencies may also impose new</font> or <font color="blue">enhanced standards</font> that     would  increase  our  costs  as  well  as  the  risks  <font color="blue">associated with</font>     non-compliance</td>
    </tr>
    <tr>
      <td>For example, we anticipate that the FDA <font color="blue">may soon finalize</font>     and  implement   &amp;quote good <font color="blue">manufacturing</font> practice, &amp;quote  or GMP, <font color="blue">regulations</font> for     <font color="blue">nutritional <font color="blue">supplements</font></font></td>
    </tr>
    <tr>
      <td>GMP <font color="blue">regulations</font> would require <font color="blue">supplements</font> to be     prepared, packaged and held in <font color="blue">compliance with certain rules</font>, and might     require <font color="blue">quality control provisions</font> similar to those in the GMP <font color="blue">regulations</font>     for drugs</td>
    </tr>
    <tr>
      <td>While our <font color="blue">manufacturing</font> <font color="blue">facilities</font> for <font color="blue">nutritional <font color="blue">supplements</font></font>     have  been  subjected  to, and passed, <font color="blue">third party</font> inspections against     anticipated GMP standards, the <font color="blue">ongoing compliance</font> required in the event that     GMP <font color="blue">regulations</font> are adopted would involve <font color="blue">additional</font> costs and <font color="blue">would present</font>     new risks <font color="blue">associated with</font> any failure to <font color="blue">comply with</font> the <font color="blue">regulations</font> in the     future</td>
    </tr>
    <tr>
      <td>If we deliver <font color="blue">products with defects</font>, our <font color="blue"><font color="blue">credibility</font> may</font> be harmed, market     <font color="blue">acceptance</font> of our <font color="blue"><font color="blue">products may</font> decrease</font> and we may be exposed to <font color="blue">liability</font>     in excess of our product <font color="blue">liability</font> <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">manufacturing</font>  and marketing of consumer and <font color="blue">professional</font>     <font color="blue"><font color="blue">diagnostic</font> products involve</font> an <font color="blue">inherent risk</font> of product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>In     addition, our product <font color="blue">development</font> and production are <font color="blue">extremely complex</font> and     <font color="blue">could expose</font> our products to defects</td>
    </tr>
    <tr>
      <td>Any <font color="blue">defects could harm</font> our <font color="blue">credibility</font>     and decrease market <font color="blue">acceptance</font> of our products</td>
    </tr>
    <tr>
      <td>In addition, our marketing     of vitamins and <font color="blue">nutritional <font color="blue">supplements</font></font> may cause us to be subjected to     various product <font color="blue">liability</font> claims, including, <font color="blue">among others</font>, claims that the     vitamins and <font color="blue">nutritional <font color="blue">supplements</font></font> have inadequate <font color="blue">warnings concerning</font>     side effects and <font color="blue">interactions with</font> other substances</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font>product     <font color="blue">liability</font> claims may exceed the amount of our <font color="blue">insurance coverage</font> or may be     <font color="blue">excluded from coverage under</font> the terms of the policy</td>
    </tr>
    <tr>
      <td>In the event that we     are held liable for a claim for which we are not indemnified, or for damages     exceeding the limits of our <font color="blue">insurance coverage</font>, that claim could <font color="blue">materially</font>     damage our business and our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our sales of branded <font color="blue">nutritional <font color="blue">supplements</font></font> have <font color="blue">been trending downward</font>     since 1998 due to the maturity of the <font color="blue">market segments</font> they serve and the age     of that <font color="blue">product line</font> and we may experience <font color="blue">further declines</font> in sales of     those products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">aggregate sales</font> of all of our brand <font color="blue">name <font color="blue">nutritional products</font></font>,     including, <font color="blue">among others</font>, Ferro-Sequels, Stresstabs, Protegra, Posture,     SoyCare, ALLBEE, and Z-BEC, have declined each year since 1998 through the     year 2005, except in 2002 when they <font color="blue">increased slightly as compared</font> to 2001</td>
    </tr>
    <tr>
      <td>We believe that these products have under-performed because they are, for     the  most  part, <font color="blue">aging brands with</font> limited brand <font color="blue">recognition</font> that face     increasing <font color="blue">private label</font> <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">overall age</font> of this <font color="blue">product line</font>     means that we are subject to future <font color="blue">distribution</font> loss for under-performing     brands, while our <font color="blue">opportunities</font> for new <font color="blue">distribution</font> on the <font color="blue">existing product</font>     lines are limited</td>
    </tr>
    <tr>
      <td>As a result we do not expect <font color="blue">significant</font> sales growth of     our existing brand <font color="blue">name <font color="blue">nutritional products</font></font> and we may experience further     declines in overall sales of our brand <font color="blue">name <font color="blue">nutritional products</font></font> in the     future</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________       Our  sales  of  <font color="blue">specific vitamins</font> and <font color="blue">nutritional <font color="blue">supplements</font></font> could be     <font color="blue">negatively impacted by <font color="blue">media attention</font></font> or other news <font color="blue">development</font>s that     challenge  the safety and <font color="blue">effective</font>ness of those <font color="blue">specific vitamins</font> and     <font color="blue">nutritional <font color="blue">supplements</font></font></td>
    </tr>
    <tr>
      <td>Most growth in the vitamin and <font color="blue">nutritional supplement industry</font> is     attributed to <font color="blue">new products</font> that tend to <font color="blue">generate greater attention</font> in the     <font color="blue">marketplace than</font> do <font color="blue">older products</font></td>
    </tr>
    <tr>
      <td>Positive <font color="blue">media attention</font> resulting from     <font color="blue">new scientific studies</font> or <font color="blue">announcements</font> can <font color="blue">spur rapid growth</font> in individual     segments of the market, and <font color="blue">also impact</font> individual brands</td>
    </tr>
    <tr>
      <td>Conversely, news     that <font color="blue">challenges</font> individual segments or products can have a <font color="blue">negative impact</font>     on the <font color="blue">industry overall as well as on sales</font> of the <font color="blue">challenged segments</font> or     products</td>
    </tr>
    <tr>
      <td>Most of our vitamin and <font color="blue">nutritional <font color="blue">supplements</font></font> products serve     well-established <font color="blue">market segments</font> and, absent unforeseen new <font color="blue">development</font>s or     trends, are not expected to <font color="blue">benefit from</font> rapid growth</td>
    </tr>
    <tr>
      <td>A few of our vitamin     and <font color="blue">nutritional products</font> are <font color="blue">newer products</font> that are more likely to be the     subject of <font color="blue">new scientific studies</font> or <font color="blue">announcements</font>, which could be either     positive or negative</td>
    </tr>
    <tr>
      <td>News or other <font color="blue">development</font>s that challenge the safety     or <font color="blue">effective</font>ness of these <font color="blue">products could negatively impact</font> the <font color="blue">profitability</font>     of our vitamin and <font color="blue">nutritional <font color="blue">supplements</font></font> business</td>
    </tr>
    <tr>
      <td>We could suffer monetary damages, incur substantial costs or be prevented     from using <font color="blue">technologies</font> important to our <font color="blue">products as</font> a result of legal     <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>We are involved in various legal <font color="blue">proceedings</font> arising out of our     consumer <font color="blue"><font color="blue">diagnostic</font>s</font>, <font color="blue">nutritional <font color="blue">supplements</font></font> and <font color="blue">professional</font> <font color="blue"><font color="blue">diagnostic</font>s</font>     business</td>
    </tr>
    <tr>
      <td>Because of the nature of our business, we may be subject at any     particular time to commercial disputes, consumer product claims or various     other lawsuits arising in the <font color="blue">ordinary course</font> of our business, including     <font color="blue">employment matters</font>, and expect that this <font color="blue">will continue</font> to be the case in the     future</td>
    </tr>
    <tr>
      <td>Such lawsuits <font color="blue">generally</font> seek damages, sometimes in substantial     amounts, for commercial or <font color="blue">personal injuries allegedly suffered</font> and can     include claims for punitive or other <font color="blue">special damages</font></td>
    </tr>
    <tr>
      <td>An adverse ruling or     rulings  in  one  or  more such lawsuits could, individually or in the     aggregate,  have a material adverse effect on our sales, <font color="blue">operations</font> or     <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">aggressively defend</font> our patent and     other  <font color="blue">intellectual</font>  property  rights</td>
    </tr>
    <tr>
      <td>This  often  <font color="blue">involves bringing</font>     <font color="blue">infringement</font> or other commercial claims against <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>These suits     can be expensive and result in <font color="blue">counterclaims challenging</font> the validity of our     patents and other rights</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that these lawsuits or any     <font color="blue">future lawsuits</font> relating to our <font color="blue">businesses</font> will not have a material adverse     effect on us</td>
    </tr>
    <tr>
      <td>The <font color="blue">profitability</font> of our consumer products <font color="blue">businesses</font> may suffer if we are     unable  to establish and maintain close working <font color="blue">relationships</font> with our     customers</td>
    </tr>
    <tr>
      <td>For the years ended <font color="blue">December </font>31, 2005 and 2004, <font color="blue">approximately</font> 58prca     and  65prca, <font color="blue">respectively</font>, of our <font color="blue">net <font color="blue">product sales</font></font> were <font color="blue">derived from</font> our     consumer  products business, <font color="blue">which consists</font> of our <font color="blue">consumer <font color="blue">diagnostic</font></font>     products and vitamin and <font color="blue">nutritional <font color="blue">supplements</font></font> segments</td>
    </tr>
    <tr>
      <td>These <font color="blue">businesses</font>     rely to a great extent on close working <font color="blue">relationships</font> with our customers     rather  than  long-term  exclusive  <font color="blue">contractual</font> <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Customer     </font><font color="blue">concentration</font> in these <font color="blue">businesses</font> is <font color="blue">relatively</font> high, especially in our     vitamin and <font color="blue">nutritional <font color="blue">supplements</font></font> segment where <font color="blue">two customers accounted</font>     for <font color="blue">approximately</font> 61prca of sales during 2005</td>
    </tr>
    <tr>
      <td>In addition, customers of our     branded and <font color="blue">private label</font> consumer products <font color="blue">businesses</font> purchase products     <font color="blue">through purchase orders only</font> and are not obligated to make <font color="blue">future purchases</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">therefore rely on</font> our ability to deliver <font color="blue">quality products on</font> time in     order to retain and <font color="blue">generate customers</font></td>
    </tr>
    <tr>
      <td>If we fail to meet our customers &amp;apos      needs or <font color="blue">expectations</font>, whether due to <font color="blue">manufacturing</font> issues that affect     quality or <font color="blue">capacity issues</font> that result in <font color="blue">late shipments</font>, we will harm our     reputation  and  customer  <font color="blue">relationships</font>  and  likely  <font color="blue">lose customers</font></td>
    </tr>
    <tr>
      <td>Additionally, if we are unable to maintain close working <font color="blue">relationships</font> with     our customers, sales of all of our products and our ability to <font color="blue">successfully</font>     launch <font color="blue">new products</font> could suffer</td>
    </tr>
    <tr>
      <td>The loss of a <font color="blue">major customer</font> and the     failure to generate new accounts could <font color="blue">significant</font>ly reduce our revenues or     <font color="blue">prevent us from</font> achieving projected growth</td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________       The  <font color="blue">profitability</font>  of  our consumer products <font color="blue">businesses</font> may suffer if     Pfizer Inc</td>
    </tr>
    <tr>
      <td>is unable to <font color="blue">successfully</font> market and sell its e</td>
    </tr>
    <tr>
      <td>Under the terms of a <font color="blue">manufacturing</font>, packaging and supply <font color="blue">agreement</font>     that we <font color="blue">entered into with</font> Pfizer Inc, <font color="blue">through one</font> of its wholly-owned     <font color="blue">subsidiaries</font>, Pfizer purchases its non-digital e</td>
    </tr>
    <tr>
      <td><font color="blue">t pregnancy tests</font> from us     through June 6, 2009</td>
    </tr>
    <tr>
      <td>Additionally, pursuant to the terms of a five-year     supply <font color="blue">agreement</font> entered into in <font color="blue">December </font>2003, as amended on June 1, 2005,     we  currently  supply Pfizer with a <font color="blue">digital version</font> of its e</td>
    </tr>
    <tr>
      <td>t brand     <font color="blue">pregnancy tests on</font> an <font color="blue">exclusive basis</font></td>
    </tr>
    <tr>
      <td>The amount of revenues or profits     that we <font color="blue">generate under</font> these <font color="blue">agreement</font>s will depend on the volume of orders     that  we  receive  from  Pfizer</td>
    </tr>
    <tr>
      <td>As  a result, if Pfizer is unable to     <font color="blue">successfully</font> market and sell its e</td>
    </tr>
    <tr>
      <td><font color="blue">t pregnancy tests</font>, or if other events     <font color="blue"><font color="blue">adversely</font> affect</font> the volume of Pfizerapstas sales of its e</td>
    </tr>
    <tr>
      <td><font color="blue">t pregnancy tests</font>,     then our <font color="blue">future revenues</font> and <font color="blue">profit may</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>Because sales of our <font color="blue">private label</font> <font color="blue">nutritional <font color="blue">supplements</font></font> are <font color="blue">generally</font>     made  at  low  margins, the <font color="blue">profitability</font> of these <font color="blue"><font color="blue">products may</font> suffer</font>     <font color="blue">significant</font>ly as a result of <font color="blue">relatively</font> small increases in raw material or     other <font color="blue">manufacturing</font> costs</td>
    </tr>
    <tr>
      <td>Sales of our <font color="blue">private label</font> <font color="blue">nutritional <font color="blue">supplements</font></font>, which for the     years ended <font color="blue">December </font>31, 2005 and 2004, provided <font color="blue">approximately</font> 16prca and 17prca,     <font color="blue">respectively</font>, of our <font color="blue">net <font color="blue">product sales</font></font>, generate low profit margins</td>
    </tr>
    <tr>
      <td>We rely     on our ability to <font color="blue">efficiently mass</font> produce <font color="blue">nutritional <font color="blue">supplements</font></font> in order     to make <font color="blue"><font color="blue">meaningful</font> profits from</font> these products</td>
    </tr>
    <tr>
      <td>Changes in raw material or     other <font color="blue">manufacturing</font> costs can <font color="blue">drastically</font> cut into or eliminate the profits     <font color="blue">generated from</font> the sale of a <font color="blue">particular product</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">private label</font>     <font color="blue">nutritional <font color="blue">supplements</font></font> business is <font color="blue"><font color="blue">also highly competitive</font> such</font> that our     ability to <font color="blue">raise prices as</font> a result of <font color="blue">increased costs</font> is limited</td>
    </tr>
    <tr>
      <td><font color="blue">Customers     </font><font color="blue">generally</font> purchase <font color="blue">private label</font> products via purchase order, not through     long-term contracts, and they <font color="blue">often purchase</font> these <font color="blue">products from</font> the lowest     bidder  on a <font color="blue">product by product basis</font></td>
    </tr>
    <tr>
      <td>The internet has <font color="blue">enhanced price</font>     <font color="blue">competition</font> among <font color="blue">private label</font> <font color="blue">manufacture</font>rs through the advent of on-line     auctions,  where <font color="blue">customers will auction off</font> the right to <font color="blue">manufacture</font> a     <font color="blue">particular product</font> to the <font color="blue">lowest bidder</font></td>
    </tr>
    <tr>
      <td>The resulting margin erosion in our     <font color="blue">nutritionals</font> business has resulted in a reduction in our overall gross     margin and <font color="blue">contributed</font> to our losses in 2005</td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial condition</font> or results of <font color="blue">operations</font> may be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font>     <font color="blue">by international</font> business risks</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>42prca and 40prca of our <font color="blue">net revenues</font> were <font color="blue">generated from</font>     outside the <font color="blue"><font color="blue">United States</font> </font>for the years ended <font color="blue">December </font>31, 2005 and 2004,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>A  <font color="blue">significant</font>  number  of  our  employees,  including     <font color="blue">manufacturing</font>, sales, support and research and <font color="blue">development</font> personnel, are     located in <font color="blue">foreign countries</font>, including England, Japan, China, Ireland and     Israel</td>
    </tr>
    <tr>
      <td><font color="blue">Conducting </font>business outside of the <font color="blue"><font color="blue">United States</font> </font><font color="blue">subjects us</font> to     <font color="blue">numerous risks</font>, including:          •                 <font color="blue">increased costs</font> or <font color="blue"><font color="blue">reduced revenue</font> as</font> a result of movements in                 <font color="blue">foreign currency exchange rates</font>;          •                 <font color="blue">decreased liquidity</font> resulting from longer accounts receivable                 <font color="blue">collection cycles typical</font> of <font color="blue">foreign countries</font>;          •                 <font color="blue">lower productivity</font> resulting from <font color="blue">difficult</font>ies managing our                 sales, support and research and <font color="blue">development</font> <font color="blue">operations</font> across                 many countries;          •                 lost  revenues resulting from <font color="blue">difficult</font>ies <font color="blue">associated with</font>                 enforcing <font color="blue">agreement</font>s and <font color="blue">collecting receivables through foreign</font>                 <font color="blue">legal systems</font>;          •                 lost  revenues  resulting  from  the <font color="blue">imposition by foreign</font>                 <font color="blue">governments</font> of <font color="blue">trade protection measures</font>;          •                 <font color="blue">higher cost</font> of sales resulting <font color="blue">from import</font> or <font color="blue">export licensing</font>                 <font color="blue">requirements</font>;                                         19       _________________________________________________________________       •            <font color="blue">lost revenues</font> or other <font color="blue">adverse affects as</font> a result of economic or            <font color="blue">political instability</font> in or affecting <font color="blue">foreign countries</font> in which we            sell our products or operate; and     •            <font color="blue">adverse effects</font> resulting from changes in <font color="blue">foreign regulatory</font> or other            <font color="blue">laws affecting</font> the sales of our products or our foreign <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Because our business <font color="blue">relies heavily on</font> foreign <font color="blue">operations</font> and revenues,     changes  in <font color="blue">foreign currency exchange rates</font> and our ability to convert     <font color="blue">currencies may negatively affect</font> our <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">relies heavily on</font> our foreign <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Four of our     <font color="blue">manufacturing</font>  <font color="blue">operations</font>  are conducted outside the <font color="blue">United States</font>, in     Bedford, England; Shanghai, China; Matsudo, Japan and Yavne, Israel</td>
    </tr>
    <tr>
      <td>We have     <font color="blue">consolidated</font> much of our <font color="blue">cardiovascular</font> related research and <font color="blue">development</font> in     Scotland and ultimately we intend to establish a <font color="blue">significant</font> <font color="blue">manufacturing</font>     operation  there</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font> 42prca and 40prca of our <font color="blue">net revenues</font> were     <font color="blue">generated from</font> outside the <font color="blue"><font color="blue">United States</font> </font>for the years ended <font color="blue">December </font>31,     2005 and 2004, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our Clearblue </font><font color="blue">pregnancy test <font color="blue">product sales</font></font> have     <font color="blue">historically been</font> much <font color="blue">stronger outside</font> the <font color="blue">United States</font>, with 68prca of net     <font color="blue">product sales</font> of these <font color="blue">products coming from outside</font> the <font color="blue"><font color="blue">United States</font> </font>during     the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>In addition, the Abbott <font color="blue">rapid <font color="blue"><font color="blue">diagnostic</font>s</font></font>     business, which we acquired on <font color="blue">September </font>30, 2003, generates a majority of     its  sales  outside  the <font color="blue">United States</font>, and all of the revenues of the     <font color="blue">Determine </font>business are <font color="blue">derived outside</font> of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Because of our     foreign <font color="blue">operations</font> and foreign sales, we face exposure to movements in     <font color="blue">foreign currency exchange rates</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">primary exposures</font> are related to the     <font color="blue">operations</font> of our European <font color="blue">subsidiaries</font></td>
    </tr>
    <tr>
      <td>With our recent <font color="blue">acquisition</font> of the     <font color="blue">Determine </font>business and the <font color="blue">establishment</font> of our <font color="blue">manufacturing</font> <font color="blue">facility</font> in     Shanghai, we anticipate that our <font color="blue">currency exposures</font> related to the yen and     the Chinese <font color="blue">yuan will become</font> more <font color="blue">significant</font> to our results than in prior     periods</td>
    </tr>
    <tr>
      <td>Should it be consummated, our pending <font color="blue">acquisition</font> of the rapid     <font color="blue">diagnostic</font> business of <font color="blue">ACON Laboratories </font>for most major markets, which     includes the <font color="blue">acquisition</font> of a major <font color="blue">manufacturing</font> <font color="blue">facility</font> in China, will     <font color="blue">also increase</font> our exposure to the Chinese yuan</td>
    </tr>
    <tr>
      <td>These <font color="blue">exposures may</font> change     over time as business <font color="blue">practices evolve</font> and could result in <font color="blue">increased costs</font>     or <font color="blue">reduced revenue</font> and <font color="blue">could impact</font> our actual <font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>Intense <font color="blue"><font color="blue">competition</font> could reduce</font> our market share or limit our ability to     <font color="blue">increase market</font> share, <font color="blue">which could impair</font> the sales of our products and harm     our <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">medical products industry</font> is <font color="blue">rapidly evolving</font> and <font color="blue">development</font>s     are expected to <font color="blue">continue at</font> a rapid pace</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in this industry,     which includes both our consumer <font color="blue"><font color="blue">diagnostic</font>s</font> and <font color="blue">professional</font> <font color="blue"><font color="blue">diagnostic</font>s</font>     <font color="blue">businesses</font>,  is  intense  and expected to increase as <font color="blue">new products</font> and     <font color="blue">technologies</font> become available and new <font color="blue">competitors</font> enter the market</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font> <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>and abroad are numerous and include, among     others, <font color="blue">diagnostic</font> testing and medical products companies, <font color="blue">universities</font> and     other research <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>Our future <font color="blue">success depends</font> upon maintaining a     <font color="blue">competitive position</font> in the <font color="blue">development</font> of products and <font color="blue">technologies</font> in our     areas of focus</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may:          •                 develop <font color="blue">technologies</font> and products that are more <font color="blue">effective</font> than                 our  products  or that render our <font color="blue">technologies</font> or products                 obsolete or <font color="blue">noncompetitive</font>;          •                 obtain <font color="blue">patent protection</font> or other <font color="blue">intellectual</font> <font color="blue">property rights</font>                 that would <font color="blue">prevent us from</font> developing our <font color="blue">potential products</font>; or          •                 obtain <font color="blue">regulatory approval</font> for the <font color="blue">commercialization</font> of their                 products more rapidly or <font color="blue">effective</font>ly than we do</td>
    </tr>
    <tr>
      <td>Also, the <font color="blue">possibility</font> of patent disputes with <font color="blue">competitors</font> holding     foreign patent rights may limit or delay expansion <font color="blue">possibilities</font> for our     <font color="blue"><font color="blue">diagnostic</font>s</font> <font color="blue">businesses</font> in certain foreign <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>In addition, many     of our existing or potential <font color="blue">competitors</font> have or may have <font color="blue">substantially</font>     <font color="blue">greater research</font> and                                         20       _________________________________________________________________       <font color="blue">development</font> capabilities, clinical, <font color="blue">manufacturing</font>, regulatory and marketing     experience and financial and <font color="blue">managerial resources</font></td>
    </tr>
    <tr>
      <td>The market for the sale of vitamins and <font color="blue">nutritional <font color="blue">supplements</font></font> is     <font color="blue">also highly competitive</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">competition</font> is <font color="blue">based principally upon price</font>,     quality of products, customer service and <font color="blue">marketing support</font></td>
    </tr>
    <tr>
      <td>There are     <font color="blue">numerous companies</font> in the vitamins and <font color="blue">nutritional <font color="blue">supplements</font></font> industry     <font color="blue">selling products</font> to retailers such as mass merchandisers, drug store chains,     <font color="blue">independent</font> drug stores, supermarkets, groceries and <font color="blue">health food stores</font></td>
    </tr>
    <tr>
      <td>As     most of these companies are privately held, we are unable to obtain the     information <font color="blue">necessary</font> to <font color="blue">assess precisely</font> the size and success of these     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>However,  we  believe  that a number of our <font color="blue">competitors</font>,     particularly <font color="blue">manufacture</font>rs of <font color="blue">nationally advertised</font> brand <font color="blue">name products</font>, are     <font color="blue">substantially</font> larger than we are and have <font color="blue">greater financial resources</font></td>
    </tr>
    <tr>
      <td>The rights we rely upon to protect the <font color="blue">intellectual</font> property underlying our     <font color="blue">products may</font> not be adequate, which could enable <font color="blue">third parties</font> to use our     <font color="blue">technology</font> and would reduce our ability to compete in the market</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to develop or acquire     <font color="blue">commercially</font>  valuable  patent  rights and to protect our <font color="blue">intellectual</font>     property</td>
    </tr>
    <tr>
      <td>Our <font color="blue">patent position</font> is <font color="blue">generally</font> uncertain and <font color="blue">involves complex</font>     legal and factual questions</td>
    </tr>
    <tr>
      <td>The degree of present and <font color="blue">future protection</font> for     our <font color="blue"><font color="blue">proprietary</font> rights</font> is uncertain</td>
    </tr>
    <tr>
      <td>The risks and <font color="blue">uncertainties</font> that we <font color="blue">face with respect</font> to our patents     and other <font color="blue"><font color="blue">proprietary</font> rights</font> include the following:          •                 the pending patent <font color="blue">applications</font> we have filed or to which we                 have <font color="blue">exclusive rights may</font> not result in issued patents or may                 take <font color="blue">longer than</font> we expect to result in issued patents;          •                 the claims of any <font color="blue">patents which</font> are <font color="blue">issued may</font> not provide                 <font color="blue"><font color="blue">meaningful</font> protection</font>;          •                 we  may  not  be  able  to  develop <font color="blue">additional</font> <font color="blue">proprietary</font>                 <font color="blue">technologies</font> that are patentable;          •                 the <font color="blue">patents licensed</font> or issued to us or our customers may not                 provide a <font color="blue">competitive advantage</font>;          •                 other <font color="blue">parties may challenge patents</font> or patent <font color="blue">applications</font>                 licensed or issued to us or our customers;          •                 <font color="blue">patents issued</font> to other <font color="blue">companies may harm</font> our ability to do                 business; and          •                 other companies may <font color="blue">design around</font> <font color="blue">technologies</font> we have patented,                 licensed or developed</td>
    </tr>
    <tr>
      <td>In addition to patents, we rely on a <font color="blue">combination</font> of <font color="blue">trade secrets</font>,     nondisclosure <font color="blue">agreement</font>s and other <font color="blue">contractual</font> provisions and technical     measures to protect our <font color="blue">intellectual</font> <font color="blue">property rights</font></td>
    </tr>
    <tr>
      <td>Nevertheless, these     <font color="blue">measures may</font> not be adequate to safeguard the <font color="blue">technology</font> underlying our     products</td>
    </tr>
    <tr>
      <td>If they do not protect our rights, <font color="blue">third parties</font> could use our     <font color="blue">technology</font> and our ability to compete in the <font color="blue">market would</font> be reduced</td>
    </tr>
    <tr>
      <td>In     addition,  employees,  <font color="blue">consultants</font>  and  others who <font color="blue">participate</font> in the     <font color="blue">development</font> of our <font color="blue">products may</font> breach their <font color="blue">agreement</font>s with us regarding     our <font color="blue">intellectual</font> property and we may not have <font color="blue">adequate remedies</font> for the     breach</td>
    </tr>
    <tr>
      <td>We also may not be able to <font color="blue">effective</font>ly protect our <font color="blue">intellectual</font>     <font color="blue">property rights</font> in some <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>For a variety of reasons, we may     decide  not  to  file for patent, copyright or trademark protection or     prosecute potential <font color="blue">infringement</font>s of our patents</td>
    </tr>
    <tr>
      <td>We also realize that our     <font color="blue">trade secrets</font> may become known through other means not <font color="blue">currently foreseen by</font>     us</td>
    </tr>
    <tr>
      <td><font color="blue">Despite  </font>our  efforts  to  protect our <font color="blue">intellectual</font> property, our     <font color="blue">competitors</font> or customers may <font color="blue">independent</font>ly develop similar or <font color="blue">alternative</font>     <font color="blue">technologies</font> or products that are equal or superior to our <font color="blue">technology</font> and     <font color="blue">products without infringing on</font> any of our <font color="blue">intellectual</font> <font color="blue">property rights</font> or     <font color="blue">design around</font> our <font color="blue">proprietary</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________       Claims by other companies that our products infringe on their <font color="blue">proprietary</font>     rights could <font color="blue"><font color="blue">adversely</font> affect</font> our ability to sell our products and increase     our costs</td>
    </tr>
    <tr>
      <td><font color="blue">Substantial </font><font color="blue">litigation</font> over <font color="blue">intellectual</font> <font color="blue">property rights</font> exists in     both the consumer and <font color="blue">professional</font> <font color="blue">diagnostic</font> <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>We expect that our     products and products in these <font color="blue">industries</font> could be <font color="blue">increasingly</font> subject to     <font color="blue">third party</font> <font color="blue">infringement</font> claims as the number of <font color="blue">competitors</font> grows and the     <font color="blue">functionality</font> of products and <font color="blue">technology</font> in <font color="blue">different industry segments</font>     overlaps</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may currently</font> have, or <font color="blue">may eventually</font> be issued,     <font color="blue">patents on which</font> our products or <font color="blue">technology</font> may infringe</td>
    </tr>
    <tr>
      <td>Any of these third     parties might make a claim of <font color="blue">infringement</font> <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">litigation</font> could</font>     result  in  the <font color="blue">expenditure</font> of <font color="blue">significant</font> financial resources and the     diversion of <font color="blue">management</font>apstas time and resources</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">litigation</font> in     which we are accused of <font color="blue">infringement</font> may cause <font color="blue">negative publicity</font>, have an     <font color="blue">impact on</font> prospective customers, cause <font color="blue">product shipment delays</font> or require us     to develop non-infringing <font color="blue">technology</font>, make substantial payments to third     parties, or <font color="blue">enter into</font> royalty or license <font color="blue">agreement</font>s, which may not be     available  on  acceptable  terms,  or at all</td>
    </tr>
    <tr>
      <td>If a successful claim of     <font color="blue">infringement</font> was made <font color="blue">against us</font> and we could not develop non-infringing     <font color="blue">technology</font> or license the infringed or similar <font color="blue">technology</font> on a timely and     cost-<font color="blue">effective</font> basis, our revenue may decrease and we could be exposed to     legal actions by our customers</td>
    </tr>
    <tr>
      <td>We have initiated, and may need to further initiate, lawsuits to protect or     enforce our patents and other <font color="blue">intellectual</font> <font color="blue">property rights</font>, which could be     expensive and, if we lose, could cause us to lose some of our <font color="blue">intellectual</font>     <font color="blue">property rights</font>, which would reduce our ability to compete in the market</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on patents</font> to protect a portion of our <font color="blue">intellectual</font> property     and our <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>In order to protect or enforce our patent     rights, we may initiate patent <font color="blue">litigation</font> against <font color="blue">third parties</font>, such as     <font color="blue">infringement</font> suits or interference <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be <font color="blue">necessary</font>     to:          •                 assert claims of <font color="blue">infringement</font>;          •                 enforce our patents;          •                 protect our <font color="blue">trade secrets</font> or know-how; or          •                 determine  the  <font color="blue">enforceability</font>,  scope and validity of the                 <font color="blue"><font color="blue">proprietary</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>Currently,  we  have  initiated  a  number of <font color="blue">lawsuits against</font>     <font color="blue">competitors</font>  who  we  believe to be <font color="blue">selling products</font> that infringe our     <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">current lawsuits</font> and any other lawsuits that we     <font color="blue">initiate could</font> be expensive, take <font color="blue">significant</font> time and divert <font color="blue">management</font>apstas     <font color="blue">attention from</font> other business concerns</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>also puts our patents at     risk  of  being  invalidated  or  interpreted  narrowly and our patent     <font color="blue">applications</font> at risk of not issuing</td>
    </tr>
    <tr>
      <td>Additionally, we <font color="blue">may provoke third</font>     parties to assert claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Patent law relating to the scope of claims in the <font color="blue">technology</font> fields     in which we operate is <font color="blue">still evolving</font> and, consequently, <font color="blue">patent position</font>s in     our industry are <font color="blue">generally</font> uncertain</td>
    </tr>
    <tr>
      <td>We may not prevail in any of these     suits  and  the  damages or other <font color="blue">remedies awarded</font>, if any, may not be     <font color="blue">commercially</font> valuable</td>
    </tr>
    <tr>
      <td>During the course of these suits, there may be public     <font color="blue">announcements</font>  of  the  results of hearings, motions and other interim     <font color="blue">proceedings</font> or <font color="blue">development</font>s in the <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">securities analysts</font> or     investors perceive any of these results to be negative, our stock price     <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2005, we learned that the Securities and Exchange Commission, or     the SEC, had issued a formal order of <font color="blue">investigation</font> in <font color="blue"><font color="blue">connection</font> with</font> the     <font color="blue">previously</font> disclosed revenue <font color="blue">recognition</font> matter at one of our <font color="blue">diagnostic</font>     divisions</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> what the outcome of this <font color="blue">investigation</font> will be</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2005, we learned that the SEC had issued a formal order     of  <font color="blue">investigation</font>  in <font color="blue"><font color="blue">connection</font> with</font> the <font color="blue">previously</font> disclosed revenue     <font color="blue">recognition</font> matter at one of our <font color="blue">diagnostic</font> divisions, and we <font color="blue">subsequently</font>     received a subpoena for <font color="blue">documents</font></td>
    </tr>
    <tr>
      <td>We believe that we fully responded to the                                         22       _________________________________________________________________       subpoena  and  we  will  continue  to  fully  <font color="blue">cooperate with</font> the SECapstas     <font color="blue">investigation</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> whether the SEC will seek <font color="blue">additional</font>     information or what the outcome of its <font color="blue">investigation</font> will be</td>
    </tr>
    <tr>
      <td>Non-<font color="blue">competition</font> <font color="blue">obligations</font> and other <font color="blue">restrictions</font> will limit our ability to     take full advantage of our <font color="blue">management</font> team, the <font color="blue">technology</font> we own or license     and our research and <font color="blue">development</font> capabilities</td>
    </tr>
    <tr>
      <td>Members of our <font color="blue">management</font> team have had <font color="blue">significant</font> experience in     the diabetes field</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">technology</font> we own or <font color="blue">license may</font> have     potential  <font color="blue">applications</font> to this field and our research and <font color="blue">development</font>     <font color="blue">capabilities could</font> be applied to this field</td>
    </tr>
    <tr>
      <td>However, in <font color="blue">conjunction</font> with     our split-off from Inverness Medical Technology, Inc, or IMT, we agreed not     to <font color="blue">compete with</font> IMT and Johnson &amp; Johnson in the field of <font color="blue">diabetes through</font>     2011</td>
    </tr>
    <tr>
      <td>Ron Zwanziger, our Chairman, Chief Executive Officer     and  President,  and two of our senior <font color="blue">scientists</font>, Dr</td>
    </tr>
    <tr>
      <td><font color="blue">David Scott </font>and     Dr</td>
    </tr>
    <tr>
      <td>Jerry McAleer, have entered into consulting <font color="blue">agreement</font>s with IMT that     impose  similar  <font color="blue">restrictions</font></td>
    </tr>
    <tr>
      <td>Further, our license <font color="blue">agreement</font> with IMT     prevents  <font color="blue">us from using</font> any of the licensed <font color="blue">technology</font> in the field of     diabetes</td>
    </tr>
    <tr>
      <td>As a result of these <font color="blue">restrictions</font>, we cannot pursue <font color="blue">opportunities</font>     in the field of diabetes</td>
    </tr>
    <tr>
      <td>Our operating results <font color="blue">may fluctuate due</font> to <font color="blue">various factors</font> and as a result     period-to-period  <font color="blue">comparisons</font>  of  our  results of <font color="blue">operations</font> will not     <font color="blue">necessarily</font> be <font color="blue">meaningful</font></td>
    </tr>
    <tr>
      <td>Factors relating to our business make our future operating results     uncertain  and may cause them to <font color="blue">fluctuate from period</font> to period</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>factors include:          •                 the timing of new product <font color="blue">announcements</font> and <font color="blue">introduction</font>s by us                 and our <font color="blue">competitors</font>;          •                 market <font color="blue">acceptance</font> of new or <font color="blue">enhanced versions</font> of our products;          •                 changes in <font color="blue">manufacturing</font> costs or other expenses;          •                 <font color="blue">competitive pricing pressures</font>;          •                 the  gain  or  loss of <font color="blue">significant</font> <font color="blue">distribution</font> outlets or                 customers;          •                 <font color="blue">increased research</font> and <font color="blue">development</font> expenses;          •                 the timing of any future <font color="blue"><font color="blue">acquisition</font>s</font>;          •                 <font color="blue">general economic <font color="blue">conditions</font></font>; or          •                 general stock <font color="blue">market <font color="blue">conditions</font></font> or other economic or external                 factors</td>
    </tr>
    <tr>
      <td>Because our operating results may fluctuate from quarter to quarter,     it  may  be  <font color="blue">difficult</font>  for  us or our investors to predict our future     <font color="blue">performance by</font> viewing our historical operating results</td>
    </tr>
    <tr>
      <td>Period-to-period <font color="blue">comparisons</font> of our operating results may not be <font color="blue">meaningful</font>     due to our <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>We have engaged in a number of <font color="blue"><font color="blue">acquisition</font>s</font> in <font color="blue">recent years which</font>     make it <font color="blue">difficult</font> to analyze our results and to <font color="blue">compare them from period</font> to     period, including the <font color="blue"><font color="blue">acquisition</font>s</font> of the Unipath business in <font color="blue">December </font>2001,     IVC Industries, Inc</td>
    </tr>
    <tr>
      <td>in March 2002, Wampole in <font color="blue">September </font>2002, Ostex in     June 2003, <font color="blue">ABI in August </font>2003, the 2003 Abbott <font color="blue">rapid <font color="blue"><font color="blue">diagnostic</font>s</font></font> product     lines in <font color="blue">September </font>2003, Binax and Ischemia in March 2005, the <font color="blue">Determine </font>    business in June 2005, BioStar and IDT in <font color="blue">September </font>2005 and Clondiag in     <font color="blue">February </font>2006</td>
    </tr>
    <tr>
      <td>Period-to-period <font color="blue">comparisons</font> of our results of <font color="blue">operations</font> may     not be <font color="blue">meaningful</font> due to these <font color="blue"><font color="blue">acquisition</font>s</font> and are not <font color="blue">indications</font> of our     <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>Any future <font color="blue"><font color="blue">acquisition</font>s</font> will also make our results     <font color="blue">difficult</font> to <font color="blue">compare from period</font> to period in the future</td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________       Our stock price may fluctuate <font color="blue">significant</font>ly and <font color="blue">stockholders</font> who buy or sell     our <font color="blue"><font color="blue">common stock</font> may lose</font> all or part of the value of their <font color="blue">investment</font>,     <font color="blue">depending on</font> the price of our <font color="blue"><font color="blue">common stock</font> from</font> time to time</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> has <font color="blue">only been listed on</font> the <font color="blue">American Stock Exchange     </font>since November 23, 2001 and we have a limited <font color="blue">market capitalization</font></td>
    </tr>
    <tr>
      <td>As a     result,  we are currently followed by only a few market analysts and a     portion of the <font color="blue">investment</font> community</td>
    </tr>
    <tr>
      <td>Limited trading of our <font color="blue">common stock</font> may     therefore make it more <font color="blue">difficult</font> for you to sell your shares</td>
    </tr>
    <tr>
      <td>In addition, our share price may be <font color="blue">volatile due</font> to our operating     results, as well as <font color="blue">factors beyond</font> our control</td>
    </tr>
    <tr>
      <td>It is possible that     in some <font color="blue">future periods</font> the results of our <font color="blue">operations</font> will be below the     <font color="blue">expectations</font> of the <font color="blue">public market</font></td>
    </tr>
    <tr>
      <td>Furthermore, the stock market may experience     <font color="blue">significant</font> price and volume <font color="blue">fluctuations</font>, which may affect the <font color="blue">market price</font>     of our <font color="blue">common stock</font> for reasons unrelated to our operating performance</td>
    </tr>
    <tr>
      <td>The     <font color="blue">market price</font> of our <font color="blue">common stock</font> may be <font color="blue">highly volatile</font> and may be affected     <font color="blue">by factors such as</font>:          •                 our  quarterly and annual operating results, including our                 failure  to  meet  the performance estimates of securities                 analysts;          •                 changes in financial estimates of our revenues and operating                 results or buy/sell recommendations by <font color="blue">securities analysts</font>;          •                 the  timing  of  <font color="blue">announcements</font> by us or our <font color="blue">competitors</font> of                 <font color="blue">significant</font> products, contracts or <font color="blue"><font color="blue">acquisition</font>s</font> or publicity                 regarding actual or potential results or <font color="blue">performance thereof</font>;          •                 changes in general <font color="blue">conditions</font> in the economy, the financial                 markets or the <font color="blue">health care industry</font>;          •                 <font color="blue">government regulation</font> in the <font color="blue">health care industry</font>;          •                 changes in other <font color="blue">areas such as tax laws</font>;          •                 sales of substantial amounts of <font color="blue">common stock</font> or the <font color="blue">perception</font>                 that <font color="blue">such sales could</font> occur;          •                 changes in investor <font color="blue">perception</font> of our industry, our <font color="blue">businesses</font>                 or our prospects;          •                 the loss of key employees, officers or <font color="blue">directors</font>; or          •                 other <font color="blue">development</font>s affecting us or our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our organizational <font color="blue">documents</font> and <font color="blue">Delaware </font>law     may limit the ability of our <font color="blue">stockholders</font> to control our policies and effect     a change of control of our company and <font color="blue">prevent attempts by</font> our <font color="blue">stockholders</font>     to replace or remove our current <font color="blue">management</font>, which may not be in your best     interests</td>
    </tr>
    <tr>
      <td>There are provisions in our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws     that <font color="blue">may discourage</font> a <font color="blue">third party</font> from making a proposal to acquire us, even     if some of our <font color="blue">stockholders</font> might consider the proposal to be in their best     interests, and <font color="blue">prevent attempts by</font> our <font color="blue">stockholders</font> to replace or remove our     current <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>These provisions include the following:          •                 our <font color="blue">certificate</font> of <font color="blue">incorporation</font> provides for <font color="blue">three classes</font> of                 <font color="blue">directors</font> with the term of office of one class <font color="blue">expiring each</font>                 year, commonly referred to as a <font color="blue">staggered board</font></td>
    </tr>
    <tr>
      <td>By preventing                 <font color="blue">stockholders</font> from voting on the election of more than one class                 of  <font color="blue">directors</font>  at any <font color="blue">annual meeting</font> of <font color="blue">stockholders</font>, this                 <font color="blue">provision may</font> have the effect of keeping the <font color="blue">current members</font> of                 our board of <font color="blue">directors</font> in control for a <font color="blue">longer period</font> of time                 than <font color="blue">stockholders</font> may desire;                                         24       _________________________________________________________________       •            our <font color="blue">certificate</font> of <font color="blue">incorporation</font> authorizes our board of <font color="blue">directors</font> to            <font color="blue">issue shares</font> of <font color="blue">preferred stock</font> without stockholder approval and to            establish the <font color="blue">preferences</font> and rights of any <font color="blue">preferred stock</font> issued,            <font color="blue">which would allow</font> the board to issue one or more classes or series of            <font color="blue">preferred stock</font> that <font color="blue">could discourage</font> or delay a <font color="blue">tender offer</font> or            change in control</td>
    </tr>
    <tr>
      <td>•            our <font color="blue">certificate</font> of <font color="blue">incorporation</font> prohibits our <font color="blue">stockholders</font> from            filling board vacancies, calling special stockholder meetings or            taking <font color="blue">action by written consent</font>;     •            our  <font color="blue">certificate</font> of <font color="blue">incorporation</font> provides for the removal of a            <font color="blue">director only with</font> cause and by the <font color="blue">affirmative vote</font> of the holders            of 75prca or more of the <font color="blue">shares then entitled</font> to vote at an election of            our <font color="blue">directors</font>; and     •            our bylaws require <font color="blue">advance written</font> notice of <font color="blue">stockholder proposals</font>            and <font color="blue">director nominations</font></td>
    </tr>
    <tr>
      <td>Additionally, we are subject to Section 203 of the <font color="blue">Delaware </font>General     Corporation Law, which, in general, imposes <font color="blue">restrictions</font> upon acquirers of     15prca or more of our stock</td>
    </tr>
    <tr>
      <td>Finally, the board of <font color="blue">directors</font> may in the future     adopt other protective measures, such as a <font color="blue">stockholder rights</font> plan, which     <font color="blue">could delay</font>, deter or prevent a change of control</td>
    </tr>
    <tr>
      <td>Because we do not intend to <font color="blue">pay dividends</font> on our <font color="blue">common stock</font>, you will     <font color="blue">benefit from</font> an <font color="blue">investment</font> in our <font color="blue">common stock</font> only if it appreciates in     value</td>
    </tr>
    <tr>
      <td>We  <font color="blue">currently intend</font> to retain our <font color="blue">future earnings</font>, if any, to     finance the expansion of our business and do not expect to pay any cash     <font color="blue">dividends on</font> our <font color="blue">common stock</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In addition, our     senior credit <font color="blue">facility</font> currently prohibits the payment of dividends and the     <font color="blue">indenture governing</font> the terms of our <font color="blue">senior subordinated</font> notes restricts the     amount of any dividends that we may pay</td>
    </tr>
    <tr>
      <td>As a result, the success of your     <font color="blue">investment</font>  in  our  <font color="blue">common stock</font> will depend entirely upon any future     <font color="blue">appreciation</font></td>
    </tr>
    <tr>
      <td>There is no guarantee that our <font color="blue">common stock</font> will appreciate in     value or even maintain the <font color="blue">price at which</font> you purchased your shares</td>
    </tr>
  </tbody>
</table>